Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease

Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease

Saved in:

Bibliographic Details
Main Authors:	J. De Man, N. Adriaenssens, P. Van Bleyenbergh, M. Happaerts, E. André, I. Spriet, L. Dupont, N. Lorent
Format:	Article
Language:	English
Published:	International Union Against Tuberculosis and Lung Disease (The Union) 2024-07-01
Series:	IJTLD Open
Subjects:	ntm-pd infection guideline-based therapy adverse events treatment changes
Online Access:	https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00011
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease
by: A. Lemson, et al.
Published: (2024-06-01)

Evaluation of a Commercial Multiplex Real-Time PCR with Melting Curve Analysis for the Detection of <i>Mycobacterium tuberculosis</i> Complex and Five Nontuberculous Mycobacterial Species
by: Keun Ju Kim, et al.
Published: (2024-12-01)

Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report
by: Yixiao Wei, et al.
Published: (2025-01-01)

Serodiagnosis of M. abscessus species pulmonary disease using anti-glycopeptidolipid-core IgA antibody
by: T. Nii, et al.
Published: (2024-12-01)

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
by: Marek Pasek, et al.
Published: (2025-01-01)

Successful treatment of life-threatening mycobacteriosis using adjunctive gamma-interferon therapy with genetic analysis
by: P. Confalonieri, et al.
Published: (2024-01-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
by: Kazutaka Uchida, et al.
Published: (2025-01-01)

Analytical and clinical validation of a novel MeltPlus TB-NTM/RIF platform for simultaneous detection of Mycobacterium tuberculosis complex, Non-Tuberculous Mycobacteria and rifampicin resistance
by: Zhuo Wang, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Medicines for the management of overweight and obesity: A systematic review with network meta-analysis
by: Gabriela Masiero Marcon, et al.
Published: (2025-01-01)

Efficacy and safety of acupuncture with moxibustion for knee osteoarthritis: a meta-analysis of randomized controlled trials
by: Rui-Xin Zhu, et al.
Published: (2025-01-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review
by: Audra Janovskiene, et al.
Published: (2024-12-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study
by: Ruopeng Su, et al.
Published: (2024-09-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
by: Amir Sheikholeslami, et al.
Published: (2024-09-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Real-life use of delamanid: results from the European post-authorisation safety study
by: N. Schönfeld, et al.
Published: (2024-06-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Acute Infusion-Related Side Effects of Amphotericin B Lipid Complex (ABLC) in Oncohematological Patients: Real-World Data from Brazilian Reference Centers
by: Francelise Bridi Cavassin, et al.
Published: (2024-11-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Characteristics of and treatment outcomes in rifampicin-intolerant patients
by: R. Mangat, et al.
Published: (2024-04-01)

Addressing challenges in pediatric thrombosis: a comprehensive guideline development
by: Yin Wang, et al.
Published: (2025-01-01)

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
by: Samuel Pratama, et al.
Published: (2024-01-01)